AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 11241729 — intervention group
Group type: EXPERIMENTAL
Intervention: Risperidone
Number of subjects: 34
Study 11241729 — intervention group
Group type: COMPARATOR
Intervention: Olanzapine
Number of subjects: 34
Study 9206638 — intervention group
Group type: EXPERIMENTAL
Intervention: Topical decontamination with polymyxin B, tobramycin, vancomycin and amphotericin B, and perioperative i.v. prophylaxis with cefotaxim from the day before surgery until the 7th postoperative day
Number of subjects: 193
Study 9206638 — intervention group
Group type: EXPERIMENTAL
Intervention: Topical decontamination with polymyxin B, tobramycin, vancomycin and amphotericin B, and perioperative i.v. prophylaxis with cefotaxim
Number of subjects: 193
Study 9206638 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 193
Study 7959618 — intervention group
Group type: EXPERIMENTAL
Intervention: Growth hormone (GH), 0.1 IU/kg/day 6 days/week for 3 years (Group A)
Number of subjects: 30
Study 7959618 — intervention group
Group type: COMPARATOR
Intervention: Growth hormone (GH) and gonadotropin-releasing hormone agonist for the first 2 years (Group B)
Number of subjects: 30
Study 3318430 — intervention group
Group type: EXPERIMENTAL
Intervention: Nabumetone 1,000 mg given at bedtime
Number of subjects: 0
Study 3318430 — intervention group
Group type: COMPARATOR
Intervention: Naproxen 250 mg given twice daily
Number of subjects: 0
Study 31396625 — intervention group
Group type: EXPERIMENTAL
Intervention: EPA + DHA supplementation, mean dosage 1983 ± 1297 mg/d, duration 13.6 ± 6.0 weeks
Number of subjects: 1422
Study 31396625 — intervention group
Group type: COMPARATOR
Intervention: Placebo control, n = 576, took none
Number of subjects: 1422
Study 28289931 — intervention group
Group type: EXPERIMENTAL
Intervention: Acetazolamide (250 mg twice daily)
Number of subjects: 41
Study 28289931 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 41
Study 26357944 — intervention group
Group type: EXPERIMENTAL
Intervention: Apremilast 30 mg twice daily
Number of subjects: 411
Study 26357944 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 411
Study 22585012 — intervention group
Group type: EXPERIMENTAL
Intervention: Mindfulness-based stress reduction (MBSR) program for 8 weeks
Number of subjects: 146
Study 22585012 — intervention group
Group type: COMPARATOR
Intervention: Waitlist control
Number of subjects: 146
Study 21404174 — intervention group
Group type: EXPERIMENTAL
Intervention: MiniScan (test group)
Number of subjects: 0
Study 21404174 — intervention group
Group type: COMPARATOR
Intervention: Clinical judgement (control group)
Number of subjects: 0
Study 19392943 — intervention group
Group type: EXPERIMENTAL
Intervention: Swedish alcohol salespersons
Number of subjects: 0
Study 19392943 — intervention group
Group type: COMPARATOR
Intervention: Control persons
Number of subjects: 0
Study 19392943 — intervention group
Group type: EXPERIMENTAL
Intervention: Female participants
Number of subjects: 0
Study 19392943 — intervention group
Group type: EXPERIMENTAL
Intervention: Male participants
Number of subjects: 0
Study 17037893 — intervention group
Group type: EXPERIMENTAL
Intervention: Clearfil Protect Bond (Kuraray)
Number of subjects: 119
Study 17037893 — intervention group
Group type: EXPERIMENTAL
Intervention: Xeno III (Dentsply)
Number of subjects: 119
Study 17037893 — intervention group
Group type: EXPERIMENTAL
Intervention: G Bond (GC)
Number of subjects: 119
Study 17037893 — intervention group
Group type: EXPERIMENTAL
Intervention: One-Up Bond F (Tokuyama)
Number of subjects: 119
Study 17037893 — intervention group
Group type: EXPERIMENTAL
Intervention: Wire method
Number of subjects: 119
Study 17037893 — intervention group
Group type: EXPERIMENTAL
Intervention: Blade method
Number of subjects: 119
Study 15287927 — intervention group
Group type: EXPERIMENTAL
Intervention: Nateglinide monotherapy (120 mg before meals) in group 1 (diet alone or low-dose sulfonylureas)
Number of subjects: 358
Study 15287927 — intervention group
Group type: EXPERIMENTAL
Intervention: Nateglinide as add-on therapy (120 mg before meals) in group 2 (steady dose of metformin)
Number of subjects: 358
Study 12750554 — intervention group
Group type: EXPERIMENTAL
Intervention: Autologous hemoderivative vaccination
Number of subjects: 28
Study 11149499 — intervention group
Group type: EXPERIMENTAL
Intervention: Hip fracture patients (both osteosynthesis and hemiarthroplasty)
Number of subjects: 24
Study 11149499 — intervention group
Group type: COMPARATOR
Intervention: Osteosynthesis group
Number of subjects: 24
Study 11149499 — intervention group
Group type: COMPARATOR
Intervention: Age-matched controls without hip fractures
Number of subjects: 24
Study 8795327 — intervention group
Group type: EXPERIMENTAL
Intervention: Piroxicam (Feldene 'Melt')
Number of subjects: 0
Study 8795327 — intervention group
Group type: COMPARATOR
Intervention: Diclofenac suppositories
Number of subjects: 0
Study 1505903 — intervention group
Group type: EXPERIMENTAL
Intervention: Human growth hormone (4 IU daily)
Number of subjects: 38
Study 1505903 — intervention group
Group type: COMPARATOR
Intervention: Total parenteral nutrition (PN)
Number of subjects: 38
Study 6571404 — intervention group
Group type: EXPERIMENTAL
Intervention: Muscle discrimination training during a headache treatment program that included standard behavioral procedures.
Number of subjects: 38
Study 6571404 — intervention group
Group type: COMPARATOR
Intervention: Conventional program (control group).
Number of subjects: 38
Study 30690638 — intervention group
Group type: EXPERIMENTAL
Intervention: Potent D2 antagonists
Number of subjects: 184
Study 30690638 — intervention group
Group type: COMPARATOR
Intervention: Control group (not taking potent D2 antagonists)
Number of subjects: 184
Study 28976540 — intervention group
Group type: EXPERIMENTAL
Intervention: Physical Activity (PA) intervention for 9 months
Number of subjects: 308
Study 28976540 — intervention group
Group type: COMPARATOR
Intervention: Wait-list control group
Number of subjects: 308
Study 26334710 — intervention group
Group type: EXPERIMENTAL
Intervention: Higher school engagement at ages 12 and 14
Number of subjects: 906
Study 26334710 — intervention group
Group type: EXPERIMENTAL
Intervention: More alcohol consumption at ages 12 and 14
Number of subjects: 906
Study 26334710 — intervention group
Group type: EXPERIMENTAL
Intervention: Higher school engagement at age 13
Number of subjects: 906
Study 26334710 — intervention group
Group type: EXPERIMENTAL
Intervention: Alcohol use at age 13
Number of subjects: 906
Study 26334710 — intervention group
Group type: EXPERIMENTAL
Intervention: High parental support
Number of subjects: 906
Study 24698971 — intervention group
Group type: EXPERIMENTAL
Intervention: ICD with PFO monitoring (diagnostics group)
Number of subjects: 221
Study 24698971 — intervention group
Group type: COMPARATOR
Intervention: ICD without PFO monitoring (control group)
Number of subjects: 221
Study 23147973 — intervention group
Group type: EXPERIMENTAL
Intervention: Better housing quality (measured by passing housing quality items)
Number of subjects: 246
Study 23147973 — intervention group
Group type: COMPARATOR
Intervention: Substandard housing (baseline condition)
Number of subjects: 246
Study 20638231 — intervention group
Group type: EXPERIMENTAL
Intervention: Radiofrequency ablation (RFA) using ClosurePlus system
Number of subjects: 118
Study 20638231 — intervention group
Group type: EXPERIMENTAL
Intervention: Endovenous laser treatment (EVL) using EVLT system
Number of subjects: 118
Study 18003652 — intervention group
Group type: EXPERIMENTAL
Intervention: 1995 Tobacco Control Act Amendment (TCAA)
Number of subjects: 73471
Study 18003652 — intervention group
Group type: COMPARATOR
Intervention: Not applicable (control group: those not targeted by the TCAA)
Number of subjects: 73471
Study 15661480 — intervention group
Group type: EXPERIMENTAL
Intervention: 200 g/d of avocado (30.6 g of fat)
Number of subjects: 61
Study 15661480 — intervention group
Group type: COMPARATOR
Intervention: Control group (no avocado)
Number of subjects: 61
Study 15661480 — intervention group
Group type: COMPARATOR
Intervention: Both groups (experimental and control)
Number of subjects: 61
Study 11836287 — intervention group
Group type: EXPERIMENTAL
Intervention: Metformin (850 mg, twice a day)
Number of subjects: 94
Study 11836287 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 94
Study 10452407 — intervention group
Group type: EXPERIMENTAL
Intervention: Zinc supplementation (20 mg/d in a multivitamin syrup)
Number of subjects: 65
Study 10452407 — intervention group
Group type: EXPERIMENTAL
Intervention: Zinc supplementation
Number of subjects: 65
Study 7818153 — intervention group
Group type: EXPERIMENTAL
Intervention: Raised-leg exercises (20 minutes, three times a day)
Number of subjects: 245
Study 7818153 — intervention group
Group type: COMPARATOR
Intervention: Nonexercise (comparison group)
Number of subjects: 245
Study 2100774 — intervention group
Group type: EXPERIMENTAL
Intervention: Eye films with apilac
Number of subjects: 47
Study 2100774 — intervention group
Group type: EXPERIMENTAL
Intervention: Eye films with apilac combined with low‐intensity helium‐neon laser radiation
Number of subjects: 47
Study 106747 — intervention group
Group type: EXPERIMENTAL
Intervention: Flunisolide nasal spray 50 microgram q.i.d.
Number of subjects: 20
Study 106747 — intervention group
Group type: COMPARATOR
Intervention: Placebo (propylene and polyethylene glycol vehicle)
Number of subjects: 20
Study 30344071 — intervention group
Group type: EXPERIMENTAL
Intervention: Individual voice therapy
Number of subjects: 77
Study 30344071 — intervention group
Group type: EXPERIMENTAL
Intervention: Group voice therapy
Number of subjects: 77
Study 30344071 — intervention group
Group type: COMPARATOR
Intervention: Control group (no therapy)
Number of subjects: 77
Study 31237119 — intervention group
Group type: EXPERIMENTAL
Intervention: Fenofibrate (250 mg/d)
Number of subjects: 56
Study 31237119 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 56
Study 28376849 — intervention group
Group type: EXPERIMENTAL
Intervention: Study device (interactive cardiopulmonary resuscitation assist device with an automated external defibrillator)
Number of subjects: 106
Study 28376849 — intervention group
Group type: COMPARATOR
Intervention: Standard equipment
Number of subjects: 106
Study 28376849 — intervention group
Group type: EXPERIMENTAL
Intervention: Study device
Number of subjects: 106
Study 25688781 — intervention group
Group type: EXPERIMENTAL
Intervention: Eliglustat (50 or 100 mg twice daily)
Number of subjects: 40
Study 25688781 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 40
Study 23650172 — intervention group
Group type: EXPERIMENTAL
Intervention: Entecavir plus adefovir (EA)
Number of subjects: 89
Study 23650172 — intervention group
Group type: COMPARATOR
Intervention: Lamivudine plus adefovir (LA)
Number of subjects: 89
Study 21249415 — intervention group
Group type: EXPERIMENTAL
Intervention: Azithromycin (AZM) given once daily for 3 days
Number of subjects: 157
Study 21249415 — intervention group
Group type: COMPARATOR
Intervention: Cefcapene-pivoxyl (CFPN-PI) divided into three daily doses for 5 days
Number of subjects: 157
Study 19271064 — intervention group
Group type: EXPERIMENTAL
Intervention: Dexmedetomidine 10 microg (D10)
Number of subjects: 66
Study 19271064 — intervention group
Group type: EXPERIMENTAL
Intervention: Dexmedetomidine 5 microg (D5)
Number of subjects: 66
Study 19271064 — intervention group
Group type: COMPARATOR
Intervention: Control (normal saline, group N)
Number of subjects: 66
Study 17006403 — intervention group
Group type: EXPERIMENTAL
Intervention: Posterior pericardiotomy (Group A)
Number of subjects: 100
Study 17006403 — intervention group
Group type: COMPARATOR
Intervention: No posterior pericardiotomy (Group B)
Number of subjects: 100
Study 15301653 — intervention group
Group type: EXPERIMENTAL
Intervention: Monthly CBASP
Number of subjects: 82
Study 15301653 — intervention group
Group type: COMPARATOR
Intervention: Assessment only
Number of subjects: 82
Study 11702804 — intervention group
Group type: EXPERIMENTAL
Intervention: Priming dose of alcohol (0.55 g/kg)
Number of subjects: 32
Study 11702804 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 32
Study 9627768 — intervention group
Group type: EXPERIMENTAL
Intervention: Felodipine ER (2.5 mg)
Number of subjects: 216
Study 9627768 — intervention group
Group type: COMPARATOR
Intervention: Triamterene/HCTZ (25/12.5 mg)
Number of subjects: 216
Study 9627768 — intervention group
Group type: EXPERIMENTAL
Intervention: Felodipine ER
Number of subjects: 216
Study 9627768 — intervention group
Group type: COMPARATOR
Intervention: Triamterene/HCTZ
Number of subjects: 216
Study 7837013 — intervention group
Group type: EXPERIMENTAL
Intervention: Botulinum neurotoxin A treatment to the ipsilateral antagonist medial rectus
Number of subjects: 47
Study 7837013 — intervention group
Group type: COMPARATOR
Intervention: Control group (no treatment)
Number of subjects: 47
Study 3257843 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral 25-hydroxyvitamin D 50 micrograms/day
Number of subjects: 20
Study 3257843 — intervention group
Group type: COMPARATOR
Intervention: No oral 25-hydroxyvitamin D
Number of subjects: 20
Study 1593849 — intervention group
Group type: EXPERIMENTAL
Intervention: CCM-fortified orange juice (CCM-OJ)
Number of subjects: 12
Study 1593849 — intervention group
Group type: COMPARATOR
Intervention: Milk
Number of subjects: 12
Study 321000 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral ritodrine
Number of subjects: 38
Study 30817784 — intervention group
Group type: EXPERIMENTAL
Intervention: Community Support Groups (CSGs) intervention
Number of subjects: 0
Study 30817784 — intervention group
Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 0
Study 27571777 — intervention group
Group type: EXPERIMENTAL
Intervention: Coaching intervention (leaflets and three monthly coaching sessions)
Number of subjects: 0
Study 27571777 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 0
Study 25503598 — intervention group
Group type: EXPERIMENTAL
Intervention: 8% Capsaicin Patch (Qutenza)
Number of subjects: 6
Study 23400375 — intervention group
Group type: EXPERIMENTAL
Intervention: Seminal plasma insemination (SP group)
Number of subjects: 346
Study 23400375 — intervention group
Group type: COMPARATOR
Intervention: No seminal plasma insemination (noSP group)
Number of subjects: 346
Study 21955570 — intervention group
Group type: EXPERIMENTAL
Intervention: Audiovisual message broadcast in waiting rooms for 6 months
Number of subjects: 20000
Study 21955570 — intervention group
Group type: COMPARATOR
Intervention: No audiovisual message (control group)
Number of subjects: 20000
Study 19248046 — intervention group
Group type: EXPERIMENTAL
Intervention: Vatalanib 1000 mg twice-a-day with imatinib (400 mg/day for stratum A, 500 mg twice-a-day for stratum B) and hydroxyurea (500 mg twice daily)
Number of subjects: 37
Study 19248046 — intervention group
Group type: EXPERIMENTAL
Intervention: Imatinib and hydroxyurea
Number of subjects: 37
Study 19248046 — intervention group
Group type: COMPARATOR
Intervention: EIAEDs
Number of subjects: 37
Study 17443208 — intervention group
Group type: EXPERIMENTAL
Intervention: Amphetamine (5 mg initially, then 10 mg for 10 subsequent doses with 3- or 4-day separations)
Number of subjects: 33
Study 17443208 — intervention group
Group type: EXPERIMENTAL
Intervention: Amphetamine
Number of subjects: 33
Study 17443208 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 33
Study 12874615 — intervention group
Group type: EXPERIMENTAL
Intervention: Telmisartan 80 mg
Number of subjects: 682
Study 12874615 — intervention group
Group type: COMPARATOR
Intervention: Losartan 50 mg/HCTZ 12.5 mg
Number of subjects: 682
Study 10956399 — intervention group
Group type: EXPERIMENTAL
Intervention: Mailed invitation and reminder for Papanicolaou test
Number of subjects: 4802
Study 10956399 — intervention group
Group type: COMPARATOR
Intervention: Control group (no invitation during follow-up)
Number of subjects: 4802
Study 10956399 — intervention group
Group type: EXPERIMENTAL
Intervention: Total invited women (both groups)
Number of subjects: 4802
Study 10956399 — intervention group
Group type: COMPARATOR
Intervention: Total invited women (control group)
Number of subjects: 4802
Study 10956399 — intervention group
Group type: EXPERIMENTAL
Intervention: Intervention group vs Control group
Number of subjects: 4802
Study 8851875 — intervention group
Group type: EXPERIMENTAL
Intervention: Bismuth citrate/amoxicillin combination therapy (BIAM tablet; 250 mg amoxicillin base and 120 mg bismuth)
Number of subjects: 70
Study 8851875 — intervention group
Group type: COMPARATOR
Intervention: Bismuth citrate monotherapy (BI tablet; 120 mg bismuth)
Number of subjects: 70
Study 8851875 — intervention group
Group type: EXPERIMENTAL
Intervention: Bismuth citrate/amoxicillin combination therapy (BIAM)
Number of subjects: 70
Study 8851875 — intervention group
Group type: COMPARATOR
Intervention: Bismuth citrate monotherapy (BI)
Number of subjects: 70
Study 1294976 — intervention group
Group type: EXPERIMENTAL
Intervention: Cefamandole 1.5 g given one hour before surgery, repeated twice eight hourly, and throughout the operation if it lasted more than three hours
Number of subjects: 2
Study 1294976 — intervention group
Group type: COMPARATOR
Intervention: Untreated group
Number of subjects: 2
Study 1294976 — intervention group
Group type: EXPERIMENTAL
Intervention: Cefamandole 1.5 g
Number of subjects: 2
Study 6202437 — intervention group
Group type: EXPERIMENTAL
Intervention: Programmed electrical stimulation identified group 1 (20 patients) where VT or ventricular fibrillation was induced.
Number of subjects: 73
Study 6202437 — intervention group
Group type: COMPARATOR
Intervention: Prophylactic antiarrhythmic therapy assigned to group 2 (53 patients).
Number of subjects: 73
Study 31451248 — intervention group
Group type: EXPERIMENTAL
Intervention: Propolis and melatonin
Number of subjects: 0
Study 31451248 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 28240967 — intervention group
Group type: EXPERIMENTAL
Intervention: Pravastatin 40 mg
Number of subjects: 846
Study 28240967 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 846
Study 28240967 — intervention group
Group type: EXPERIMENTAL
Intervention: Pravastatin 40 mg and Placebo
Number of subjects: 846
Study 26121131 — intervention group
Group type: EXPERIMENTAL
Intervention: Mate-search priming condition
Number of subjects: 0
Study 26121131 — intervention group
Group type: EXPERIMENTAL
Intervention: Mate-guarding priming condition
Number of subjects: 0
Study 26121131 — intervention group
Group type: COMPARATOR
Intervention: Control condition
Number of subjects: 0
Study 23973555 — intervention group
Group type: EXPERIMENTAL
Intervention: Web 2.0 portal access
Number of subjects: 230
Study 23973555 — intervention group
Group type: COMPARATOR
Intervention: Control group (no portal access)
Number of subjects: 230
Study 21306612 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive training integrated in a comprehensive psychosocial programme (OPUS)
Number of subjects: 0
Study 21306612 — intervention group
Group type: COMPARATOR
Intervention: Comprehensive psychosocial programme alone
Number of subjects: 0
Study 19800445 — intervention group
Group type: EXPERIMENTAL
Intervention: MenCC primary immunization
Number of subjects: 21
Study 19800445 — intervention group
Group type: EXPERIMENTAL
Intervention: MenCC secondary immunization
Number of subjects: 21
Study 19800445 — intervention group
Group type: EXPERIMENTAL
Intervention: Nonconjugated MenC polysaccharide secondary immunization
Number of subjects: 21
Study 17067455 — intervention group
Group type: EXPERIMENTAL
Intervention: Aggressive periodontitis (AgP)
Number of subjects: 194
Study 17067455 — intervention group
Group type: EXPERIMENTAL
Intervention: Chronic periodontitis (CP)
Number of subjects: 194
Study 17067455 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 194
Study 15521668 — intervention group
Group type: EXPERIMENTAL
Intervention: Transcutaneous and intranasal electric stimulation of nasal muscles only (Group 1)
Number of subjects: 34
Study 15521668 — intervention group
Group type: EXPERIMENTAL
Intervention: Biofeedback training and home exercise program of specific nasal movements (Group 2)
Number of subjects: 34
Study 15521668 — intervention group
Group type: EXPERIMENTAL
Intervention: Surface and intranasal EMG biofeedback assisted specific strategies for nasal muscle education, home exercises and electric stimulation (Group 3)
Number of subjects: 34
Study 11228351 — intervention group
Group type: EXPERIMENTAL
Intervention: Guilty knowledge test
Number of subjects: 0
Study 11228351 — intervention group
Group type: EXPERIMENTAL
Intervention: Dual modality attention task
Number of subjects: 0
Study 9310003 — intervention group
Group type: COMPARATOR
Intervention: Positive end-expiratory pressure (PEEP) at 0 cm H2O (ZEEP)
Number of subjects: 13
Study 9310003 — intervention group
Group type: EXPERIMENTAL
Intervention: PEEP at 15 cm H2O
Number of subjects: 13
Study 9310003 — intervention group
Group type: EXPERIMENTAL
Intervention: PEEP at 15 cm H2O in patients with LIP on P-VL curve
Number of subjects: 13
Study 9310003 — intervention group
Group type: EXPERIMENTAL
Intervention: PEEP at 15 cm H2O in patients without LIP on P-VL curve
Number of subjects: 13
Study 9310003 — intervention group
Group type: EXPERIMENTAL
Intervention: High levels of PEEP
Number of subjects: 13
Study 8449203 — intervention group
Group type: EXPERIMENTAL
Intervention: Captopril (n=20)
Number of subjects: 68
Study 8449203 — intervention group
Group type: COMPARATOR
Intervention: Placebo (n=20)
Number of subjects: 68
Study 8449203 — intervention group
Group type: EXPERIMENTAL
Intervention: Conventional therapy (n=28)
Number of subjects: 68
Study 3544935 — intervention group
Group type: EXPERIMENTAL
Intervention: Ketotifen (2 mg/day) for 12 weeks
Number of subjects: 16
Study 3544935 — intervention group
Group type: COMPARATOR
Intervention: Control (not specified)
Number of subjects: 16
Study 30933616 — intervention group
Group type: EXPERIMENTAL
Intervention: Pitavastatin 1 mg
Number of subjects: 1053
Study 30933616 — intervention group
Group type: EXPERIMENTAL
Intervention: Pitavastatin 4 mg
Number of subjects: 1053
Study 28854728 — intervention group
Group type: EXPERIMENTAL
Intervention: Second dose of kisspeptin-54 (9.6 nmol/kg) administered 10 hours after the first dose.
Number of subjects: 62
Study 28854728 — intervention group
Group type: COMPARATOR
Intervention: Single dose of kisspeptin-54 (9.6 nmol/kg) administered 36 hours prior to oocyte retrieval and followed by saline 10 hours later.
Number of subjects: 62
Study 25965091 — intervention group
Group type: EXPERIMENTAL
Intervention: Dry sterile dressing
Number of subjects: 315
Study 25965091 — intervention group
Group type: EXPERIMENTAL
Intervention: Metallic silver dressing
Number of subjects: 315
Study 25965091 — intervention group
Group type: EXPERIMENTAL
Intervention: Ionic silver dressing
Number of subjects: 315
Study 23252474 — intervention group
Group type: EXPERIMENTAL
Intervention: Reflexology
Number of subjects: 385
Study 23252474 — intervention group
Group type: EXPERIMENTAL
Intervention: Lay foot manipulation
Number of subjects: 385